tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

RPRX Stock Latest News

Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
The FlyRoyalty Pharma enters $350M synthetic royalty funding agreement with Syndax
1h ago
RPRX
SNDX
Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
PremiumThe Fly
Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
2h ago
RPRX
SNDX
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & Ideas
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
3d ago
RPRX
TNYA
Royalty Pharma price target lowered to $40 from $60 at Citi
PremiumThe Fly
Royalty Pharma price target lowered to $40 from $60 at Citi
11d ago
RPRX
Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug
PremiumCompany Announcements
Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug
1M ago
8K
RPRX
PureTech Health announces FDA approval of KarXT
PremiumThe FlyPureTech Health announces FDA approval of KarXT
1M ago
BMY
PRTC
Royalty Pharma price target raised to $51 from $50 at Goldman Sachs
Premium
The Fly
Royalty Pharma price target raised to $51 from $50 at Goldman Sachs
3M ago
RPRX
DRI Healthcare Trust upgraded to Buy from Hold at Stifel
Premium
The Fly
DRI Healthcare Trust upgraded to Buy from Hold at Stifel
3M ago
RPRX
Royalty Pharma reports Q2 revenue $537M, consensus $628.52M
PremiumThe Fly
Royalty Pharma reports Q2 revenue $537M, consensus $628.52M
3M ago
RPRX
Royalty Pharma Bets Big on Voranigo’s Market Success
PremiumCompany Announcements
Royalty Pharma Bets Big on Voranigo’s Market Success
3M ago
8K
RPRX
Royalty Pharma appoints Sawaya as EVP, Head of Human Capital
PremiumThe Fly
Royalty Pharma appoints Sawaya as EVP, Head of Human Capital
3M ago
RPRX
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
4M ago
AGIO
PTCT
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
PremiumThe FlyAgios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
5M ago
AGIO
RPRX
Royalty Pharma downgraded to Neutral from Buy at UBS
Premium
The Fly
Royalty Pharma downgraded to Neutral from Buy at UBS
5M ago
RPRX
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
AGIO
ARCT
Royalty Pharma, Agios enter into vorasidenib royalty agreement
PremiumThe Fly
Royalty Pharma, Agios enter into vorasidenib royalty agreement
5M ago
AGIO
RPRX
Agios Pharmaceuticals announces $905M purchase agreement for vorasidenib royalty
PremiumThe Fly
Agios Pharmaceuticals announces $905M purchase agreement for vorasidenib royalty
5M ago
AGIO
RPRX
Cytokinetics price target lowered to $70 from $92 at Raymond James
PremiumThe Fly
Cytokinetics price target lowered to $70 from $92 at Raymond James
6M ago
CYTK
RPRX
Cytokinetics price target lowered to $72 from $108 at Needham
PremiumThe Fly
Cytokinetics price target lowered to $72 from $108 at Needham
6M ago
CYTK
RPRX
Cytokinetics and Royalty Pharma expand funding deal up to $575M
PremiumThe FlyCytokinetics and Royalty Pharma expand funding deal up to $575M
6M ago
CYTK
RPRX
Royalty Pharma to acquire royalty interest in Sanofi’s frexalimab
Premium
The Fly
Royalty Pharma to acquire royalty interest in Sanofi’s frexalimab
6M ago
SNY
RPRX
Royalty Pharma sees 2024 Porfolio Receipts $2.6B-$2.7B
Premium
The Fly
Royalty Pharma sees 2024 Porfolio Receipts $2.6B-$2.7B
6M ago
RPRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >